These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33786549)

  • 1. Management of patients with type 2 diabetes and cardiovascular disease in primary care.
    Marson A; Raffoul N; Osman R; Deed G
    Aust J Gen Pract; 2021 Apr; 50(4):238-245. PubMed ID: 33786549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of metformin on lipid parameters and on cardiovascular risk in patients with type 2 diabetes without statin therapy].
    Kender Z; Groener JB; Reismann P; Kopf S
    Orv Hetil; 2019 Aug; 160(34):1346-1352. PubMed ID: 31423831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
    Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
    Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes.
    Owen AJ; Retegan C; Rockell M; Jennings G; Reid CM
    Clin Exp Pharmacol Physiol; 2009 Jul; 36(7):643-7. PubMed ID: 19076166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study.
    Peters KE; Chubb SA; Davis WA; Davis TM
    PLoS One; 2013; 8(9):e74355. PubMed ID: 24019966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk management and its impact in Australian general practice patients with type 2 diabetes in urban and rural areas.
    Wan Q; Harris MF; Davies GP; Jayasinghe UW; Flack J; Georgiou A; Burns JR; Penn DL
    Int J Clin Pract; 2008 Jan; 62(1):53-8. PubMed ID: 17927763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
    Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing for people with type 2 diabetes and renal impairment in Australian general practice: A national cross sectional study.
    Manski-Nankervis JE; Thuraisingam S; Sluggett JK; Lau P; Blackberry I; Ilomaki J; Furler J; Bell JS
    Prim Care Diabetes; 2019 Apr; 13(2):113-121. PubMed ID: 30262176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An electronic clinical decision support tool to assist primary care providers in cardiovascular disease risk management: development and mixed methods evaluation.
    Peiris DP; Joshi R; Webster RJ; Groenestein P; Usherwood TP; Heeley E; Turnbull FM; Lipman A; Patel AA
    J Med Internet Res; 2009 Dec; 11(4):e51. PubMed ID: 20018588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.